Mikami, Yohei

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Gastroenterology and Hepatology) (Shinanomachi)

Position

Associate Professor

External Links
Page Top ▲

Academic Degrees 【 Display / hide 】

  • PhD (Medicine), Keio University, Coursework, 2012

Page Top ▲
 

Research Keywords 【 Display / hide 】

  • Inflammatory bowel disease

  • Mucosal immunology

  • Tissue regeneration and fibrosis

  • Neuroimmunology

Page Top ▲
 

Papers 【 Display / hide 】

  • Radiomics prediction of surgery in ulcerative colitis refractory to medical treatment

    Sakamoto K., Okabayashi K., Seishima R., Shigeta K., Kiyohara H., Mikami Y., Kanai T., Kitagawa Y.

    Techniques in Coloproctology 29 ( 1 ) 113 2025.12

    ISSN  11236337

    　View Summary

    Background: The surgeries in drug-resistant ulcerative colitis are determined by complex factors. This study evaluated the predictive performance of radiomics analysis on the basis of whether patients with ulcerative colitis in hospital were in the surgical or medical treatment group by discharge from hospital. Methods: This single-center retrospective cohort study used CT at admission of patients with US admitted from 2015 to 2022. The target of prediction was whether the patient would undergo surgery by the time of discharge. Radiomics features were extracted using the rectal wall at the level of the tailbone tip of the CT as the region of interest. CT data were randomly classified into a training cohort and a validation cohort, and LASSO regression was performed using the training cohort to create a formula for calculating the radiomics score. Results: A total of 147 patients were selected, and data from 184 CT scans were collected. Data from 157 CT scans matched the selection criteria and were included. Five features were used for the radiomics score. Univariate logistic regression analysis of clinical information detected a significant influence of severity (p < 0.001), number of drugs used until surgery (p < 0.001), Lichtiger score (p = 0.024), and hemoglobin (p = 0.010). Using a nomogram combining these items, we found that the discriminatory power in the surgery and medical treatment groups was AUC 0.822 (95% confidence interval (CI) 0.841–0.951) for the training cohort and AUC 0.868 (95% CI 0.729–1.000) for the validation cohort, indicating a good ability to discriminate the outcomes. Conclusions: Radiomics analysis of CT images of patients with US at the time of admission, combined with clinical data, showed high predictive ability regarding a treatment strategy of surgery or medical treatment.

  • Gut Microbiota and Interorgan Communication among the Gut, Brain, and Beyond.

    Shigehara A, Kiyohara H, Teratani T, Nakamoto N, Mikami Y, Kanai T

    Internal medicine (Tokyo, Japan)  2025.05

    ISSN  0918-2918

  • Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data

    Matsuoka, K; Motoya, S; Yamamoto, T; Matsuura, M; Fujii, T; Shinzaki, S; Mikami, Y; Arai, S; Oshima, J; Endo, Y; Yuasa, H; Hoshi, M; Sato, K; Hisamatsu, T

    JOURNAL OF GASTROENTEROLOGY  2025.04

    ISSN  0944-1174

  • First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study

    Naganuma M., Shiga H., Shimoda M., Matsuura M., Takenaka K., Fujii T., Yamamoto S., Matsubayashi M., Kobayashi T., Aoyama N., Saito D., Yokoyama K., Moriya K., Tsuchiya K., Shibui S., Kawamoto A., Shimizu H., Okamoto R., Sakamoto K., Yaguchi K., Kunisaki R., Akiyama S., Hayashi R., Hasui K., Kanmura S., Bamba S., Mishima Y., Kakimoto K., Sugimoto S., Nakazawa A., Abe T., Ogata H., Hisamatsu T., Matsuoka K., Omori T., Nakase H., Wagatsuma K., Uchiyama K., Takagi T., Fujiya M., Ueno N., Sasaki M., Takashima Y., Nanjyo S., Handa O., Shiotani A., Kanai T., Mikami Y., Sujino T., Kiyohara H., Nakamura S., Miyazaki T., Ishihara S., Andoh A., Sakuraba H., Tanaka S., Oka S., Takasago K., Kobayashi K., Betto T., Otsuka K., Nagahori M., Saito E., Fukata N.

    Journal of Gastroenterology 60 ( 4 ) 430 - 441 2025.04

    ISSN  09441174

    　View Summary

    Background: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC. Methods: This multicenter, randomized control trial was conducted across 20 Japanese medical institutions. An independent center randomly allocated patients with UC (Mayo score ≥ 6) who had not previously used biologics to three treatment groups (IFX, VED, UST). The primary endpoint was the clinical remission (CR) rate at week 12, with other endpoints including the treatment continuation rate at week 26 and adverse events (AEs). Results: From May 2021 to June 2023, 107 cases were registered, including 104 for safety and 97 for efficacy evaluation. CR rate at week 12 was 36.4% (95%CI:20.4–54.9), 32.4% (95%CI:17.4–50.5) and 43.3% (95%CI:25.5–62.6) in IFX, VED, and UST group, respectively. Continuation rates at week 26 were 50.0%(IFX), 58.3% (VED), and 82.4% (UST). AEs related to study medication were 14.7% (IFX), 16.7% (VED), and 5.9% (UST). Predictors for CR at week 12 were thiopurine use in IFX (p = 0.04), lower baseline Mayo score (p = 0.007), and lower Patient report outcome 2 (p = 0.003) at week 2 in VED. Conclusion: Due to small sample size, it is challenging to make conclusions for main endpoints from this study while our study suggested that use of thiopurines in IFX group and lower activity at enrollment in VED group may enhance treatment efficacy. (jRCT1031200329; available at https://jrct.niph.go.jp/).

  • The gut–organ axis: Clinical aspects and immune mechanisms

    Fukasawa N., Tsunoda J., Sunaga S., Kiyohara H., Nakamoto N., Teratani T., Mikami Y., Kanai T.

    Allergology International 74 ( 2 ) 197 - 209 2025.04

    ISSN  13238930

    　View Summary

    The gut-brain axis exemplifies the bidirectional connection between the intestines and the brain, as evidenced by the impact of severe stress on gastrointestinal symptoms including abdominal pain and diarrhea, and conversely, the influence of abdominal discomfort on mood. Clinical observations support the notion of the gut–brain connection, including an increased prevalence of inflammatory bowel disease (IBD) in patients with depression and anxiety, as well as the association of changes in the gut microbiota with neurological disorders such as multiple sclerosis, Parkinson's disease, stroke and Alzheimer's disease. The gut and brain communicate via complex mechanisms involving inflammatory cytokines, immune cells, autonomic nerves, and gut microbiota, which contribute to the pathogenesis in certain gut and brain diseases. Two primary pathways mediate the bidirectional information exchange between the intestinal tract and the brain: signal transduction through bloodstream factors, such as bacterial metabolites and inflammatory cytokines, and neural pathways, such as neurotransmitters and inflammatory cytokines within the autonomic nervous system through the interaction between the nerve cells and beyond. In recent years, the basic mechanisms of the pathophysiology of the gut-brain axis have been gradually elucidated. Beyond the gut-brain interaction, emerging evidence suggests the influence of the gut extends to other organs, such as the liver and lungs, through intricate inter-organ communication pathways. An increasing number of reports on this clinical and basic cross-organ interactions underscore the potential for better understanding and novel therapeutic strategies targeting inter-organs networks. Further clarification of interactions between multiorgans premises transformative insights into cross-organ therapeutic strategies.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study(Journal of Gastroenterology, (2023), 58, (751–765), 10.1007/s00535-023-02005-7)

    Matsuoka K., Yamazaki H., Nagahori M., Kobayashi T., Omori T., Mikami Y., Fujii T., Shinzaki S., Saruta M., Matsuura M., Yamamoto T., Motoya S., Hibi T., Watanabe M., Fernandez J., Fukuhara S., Hisamatsu T.

    Journal of Gastroenterology (Journal of Gastroenterology)   2024

    ISSN  09441174

    　View Summary

    Fig. 2h of the original article contained extraneous yellow data bars; Fig. 2h should appear as shown in this correction. (Figure presented.) Proportion of patients reporting a QOL as low, normal or high on SIBDQ; b severe fatigue on FACIT-F; c depression or d anxiety on the HADS scale; e absenteeism, f presenteeism, g work productivity, and h activity impairment on WPAI; and i poor sleep quality on PSQI. FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue, HADS Hospital Anxiety and Depression Scale, PSQI Pittsburgh Sleep Quality Index, QOL quality of life, SIBDQ Short Inflammatory Bowel Disease Questionnaire, WPAI Work Productivity and Activity Impairment In Fig. 3 of the original article, the labelling of ‘y’ axis was reversed (i.e., better/worse outcome); Fig. 3 should appear as shown in this correction. (Figure presented.) Associations of symptom severity and proctocolectomy with patient-reported outcomes. Data indicate SMD and their 95% confidence intervals. The fraction of variance of symptom severity explained by each outcome is shown in parentheses. The magnitude of the effect size was interpreted as: small, SMD = 0.2; medium, SMD = 0.5; and large, SMD = 0.8 [39]. Total number of patients included in the analysis were: SIBDQ (N = 1956), FACIT-F (N = 1935), HADS-D (N = 1958), HADS-A (N = 1958), WPAI-A (N = 1346), WPAI-P (N = 1346), WPAI-L (N = 1346), WPAI-I (N = 1909), and PSQI (N = 1917) (see Table 3 footnotes for breakdown by patient group). FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue, HADS Hospital Anxiety and Depression Scale (A, anxiety; D, depression), PSQI Pittsburgh Sleep Quality Index, SIBDQ Short Inflammatory Bowel Disease Questionnaire, SMD standardized mean difference, WPAI Work Productivity and Activity Impairment (A, absenteeism; I, impairment of activity; L, loss of productivity; P, presenteeism)

  • A second update on mapping the human genetic architecture of COVID-19

    Kanai M., Andrews S.J., Cordioli M., Stevens C., Neale B.M., Daly M., Ganna A., Pathak G.A., Iwasaki A., Karjalainen J., Mehtonen J., Pirinen M., Chwialkowska K., Trankiem A., Balaconis M.K., Veerapen K., Wolford B.N., Ahmad H.F., von Hohenstaufen Puoti K.A., Boer C., Boua P.R., Butler-Laporte G., Cadilla C.L., Colombo F., Douillard V., Dueker N., Dutta A.K., El-Sherbiny Y.M., Eltoukhy M.M., Esmaeeli S., Faucon A., Fave M.J., Cadenas I.F., Francescatto M., Francioli L., Franke L., Fuentes M., Durán R.G., Cabrero D.G., Harry E.N., Jansen P., Szentpéteri J.L., Kaja E., Kirk C., Kousathanas A., Krieger J.E., Patel S.K., Lemaçon A., Limou S., Lió P., Marouli E., Marttila M.M., Medina-Gómez C., Michaeli Y., Migeotte I., Mondal S., Moreno-Estrada A., Moya L., Nakanishi T., Nasir J., Pasko D., Pearson N.M., Pereira A.C., Priest J., Prijatelj V., Prokic I., Teumer A., Várnai R., Romero-Gómez M., Roos C., Rosenfeld J., Ruolin L., Schulte E.C., Schurmann C., Sedaghati-khayat B., Shaheen D., Shivanathan I., Sipeky C., Sirui Z., Striano P., Tanigawa Y., Remesal A.U., Vadgama N., Vallerga C.L., van der Laan S., Verdugo R.A., Wang Q.S., Wei Z., Zainulabid U.A., Zárate R.N., Auton A., Shelton J.F., Shastri A.J., Weldon C.H., Filshtein-Sonmez T., Coker D., Symons A.

    Nature (Nature)  621 ( 7977 ) E7 - E26 2023.09

    ISSN  00280836

  • Correction: Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD) (Journal of Gastroenterology, (2022), 57, 11, (867-878), 10.1007/s00535-022-01907-2)

    Matsuoka K., Fujii T., Okamoto R., Yamada A., Kunisaki R., Matsuura M., Watanabe K., Shiga H., Takatsu N., Bamba S., Mikami Y., Yamamoto T., Shimoyama T., Motoya S., Torisu T., Kobayashi T., Ohmiya N., Saruta M., Matsuda K., Matsumoto T., Nakase H., Maemoto A., Shinzaki S., Murata Y., Yoshigoe S., Sasaki A., Yajima T., Hisamatsu T., Nagahori M., Yukawa T., Saito D., Kawai M., Masamune A., Nagasaka M., Kazama T.

    Journal of Gastroenterology (Journal of Gastroenterology)  58 ( 6 ) 602 - 603 2023.06

    ISSN  09441174

    　View Summary

    In the original publication, ‘‘iCREST-CD Study Group’’ was not included in the author list. The correct author list is included in this Correction. Also, an Appendix listing iCREST-CD Study Group collaborators is included in this correction.

  • Correction to: Expert consensus on vaccination in patients with inflammatory bowel disease in Japan (Journal of Gastroenterology, (2023), 58, 2, (135-157), 10.1007/s00535-022-01953-w)

    Ishige T., Shimizu T., Watanabe K., Arai K., Kamei K., Kudo T., Kunisaki R., Tokuhara D., Naganuma M., Mizuochi T., Murashima A., Inoki Y., Iwata N., Iwama I., Koinuma S., Shimizu H., Jimbo K., Takaki Y., Takahashi S., Cho Y., Nambu R., Nishida D., Hagiwara S.i., Hikita N., Fujikawa H., Hosoi K., Hosomi S., Mikami Y., Miyoshi J., Yagi R., Yokoyama Y., Hisamatsu T.

    Journal of Gastroenterology (Journal of Gastroenterology)  58 ( 4 ) 431 - 432 2023.04

    ISSN  09441174

    　View Summary

    The article ‘‘Expert consensus on vaccination in patients with inflammatory bowel disease in Japan’’, written by Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Keisuke Jimbo, Yugo Takaki, Shohei Takahashi, Yuki Cho, Ryusuke Nambu, Daisuke Nishida, Shin-ichiro Hagiwara, Norikatsu Hikita, Hiroki Fujikawa, Kenji Hosoi, Shuhei Hosomi, Yohei Mikami, Jun Miyoshi, Ryusuke Yagi, Yoko Yokoyama, Tadakazu Hisamatsu, was originally published electronically on the publisher’s internet portal on 11 January 2023 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 17 January 2023 to © The Author(s) 2023 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

  • Epithelium Replacement Contributes to Field Expansion of Squamous Epithelium and Ulcerative Colitis–Associated Neoplasia

    Sugimoto S., Iwao Y., Shimoda M., Takabayashi K., Sato T., Kanai T., Mutaguchi M., Nanki K., Okabayashi K., Kawaida M., Aoki Y., Yoshimatsu Y., Kiyohara H., Kawaguchi T., Mikami Y., Fukuhara K., Sujino T., Hosoe N., Ogata H., Yahagi N.

    Gastroenterology (Gastroenterology)  162 ( 1 ) 334 - 337.e5 2022.01

    ISSN  00165085

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • RESIDENT NON-CLASSICAL MONOCYTES ARE CRITICALLY IMPORTANT FOR TISSUE DESTRUCTION IN ARTHRITIS

    Puchner, Antonia, Saferding, Victoria, Bonelli, Michael, Mikami, Yohei, Goncalves-Alves, Eliana, Binder, Nikolaus B., Steiner, Carl-Walter, Hayer, Silvia, Niederreiter, Birgit, Koenders, Marije M., Smolen, Josef S., Redlich, Kurt, Bluml, Stephan

    ANNALS OF THE RHEUMATIC DISEASES, 

    2017.03

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Elucidation of Neuro-Immune Interactions in Inflammatory Bowel Disease and Development of Novel Treatments Using New Neural Tracing Methods

    2024.06
    -
    2027.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

    　View Summary

    潰瘍性大腸炎やクローン病に代表される炎症性腸疾患の発症メカニズムは不明ですが、何らかの宿主の遺伝子変異と腸内細菌などの環境因子により免疫が過剰に活性化した結果、慢性的な腸炎が発症すると考えられております。近年、迷走神経をはじめとした自律神経を介した腸と脳の相互連間が、中枢神経の疾患であるうつ病や認知機能障害に加えて腸の疾患である炎症性腸疾患の病態形成に寄与している可能性が示唆されています。本研究では、申請者らのこれまでの報告に基づき、自律神経の機能を解析する新たな研究手法を開発し、自律神経による新たな免疫制御機構を明らかにし、腸炎に関与する新しい治療標的分子の同定を目指します。

  • Comprehensive Understanding of Host Immune-Gut Microbiota Interactions underlying Autoimmune Diseases

    2024.04
    -
    2027.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), No Setting

    　View Summary

    炎症性腸疾患やリウマチ膠原病疾患をはじめとした免疫難病において、腸内細菌等の環境因子による免疫の過剰な活性化は、病態の中核をなすメカニズムと考えられているが、これまで免疫難病病態発症・進展を誘発する病原菌は同定されておらず、免疫難病の発症メカニズムの全貌は未だ解明されていない。本研究課題では、クローン病などの炎症性腸疾患およびリウマチ膠原病疾患を含む免疫難病を自己免疫疾患スペクトラムとして捉えることで、消化管内外における慢性炎症病態の全貌を微生物と宿主免疫間の相互作用の観点から免疫学的、分子生物学的、微生物学的に解明することを目的とする。

  • Elucidation of the gut-liver-brain axis in response to host-invading bacteria and the development of treatments for gastrointestinal immune diseases

    2023.04
    -
    2026.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), No Setting

    　View Summary

    腸内細菌は、腸管疾患だけでなく中枢神経系疾患・肝疾患・皮膚疾患など腸管外病変形成においても重要な役割を担う。申請者は独自解析により腸内細菌の「体内への侵入」と「神経回路の変調」が腸内細菌による病態制御の本質であることを世界に向けて発信した。そこで、本研究提案では、消化器免疫疾患特有の腸内細菌叢が宿主免疫と神経系を介して腸管および腸管外疾患形成に及ぼす影響を分子レベルで解析し、新たな「細菌-腸-脳相関」概念を免疫難病や悪性腫瘍の新規治療法開発に繋げる。

  • Elucidation of the entropy of tissue damage in digestive organs and development of new therapeutic approaches

    2021.08
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, MIKAMI YOHEI, Grant-in-Aid for Transformative Research Areas (B), Principal investigator

    　View Summary

    In this study, we successfully established an intestinal fibrosis model induced by intestinal epithelial detachment to address the lack of model animals in the research of intestinal tissue remodeling or increase in entropy. Using the newly established intestinal fibrosis model animals and human samples, we conducted unbiased analyses of bulk RNA-seq and scRNA-seq data of stromal cells in the intestine, revealing the functional diversity of intestinal resident stromal cells. Furthermore, through integrative multi-omics analysis incorporating transcriptomic and epigenomic analyses such as ATAC-seq, we identified a novel fibroblast population that specifically arises during intestinal fibrosis.

  • Integrated elucidation of inflammatory tissue-resilience and tissue damage-entropy;Creation of innovative science for resolution of inflammation

    2021.08
    -
    2024.03

    Grants-in-Aid for Scientific Research, Hirahara Kiyoshi, Grant-in-Aid for Transformative Research Areas (B), No Setting

    　View Summary

    Aiming to understand "Inflammation Resolution”, this area has developed a research support system (Dr. Hirahara, in charge of research support), enhanced its website (Dr. Mikami, in charge of public relations), and held regular area meetings and symposia (Dr. Arai, in charge of meetings; 4 international symposia, 3 research meetings, monthly online meetings). Professor Yoichi Nabeshima (Kyoto University), Professor Yutaka Kawakami (International University of Health and Welfare, School of Medicine), and Professor Atsushi Iwama (Institute of Medical Science, University of Tokyo), who are conducting advanced research in the field of inflammation, evaluated and provided advice on the entire field.

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • 日本免疫学会研究奨励賞

    2021.12

  • 慶應医学賞 ライジング・スター賞

    2021.01

    Type of Award： Keio commendation etc.

  • 第55回日本消化器免疫学会総会　奨励賞

    2018.12

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • NIH Group Merit Award

    2016.10

  • 三四会奨励賞

    2011, Keio University School of Medicine, Sanshikai

    Type of Award： Keio commendation etc.

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2025

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2025

  • ADVANCED PHARMACOTHERAPY

    2025

  • PATHOPHYSIOLOGICAL ISSUES IN CHRONIC CARE

    2024

  • MCB(MOLECULAR CELL BIOLOGY)

    2024

display all >>

Page Top ▲